Hands-On: Crisol
Back
Services & Software
All the news and tips you need to get the most out of services, apps and software you use every day.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
In latest family venture, Trump Organization launches smartphone
The Trump Organization's latest business venture is about a golden phone and a wireless plan. This mobile venture will operate on three American wireless carriers; AT&T, T-Mobile and Verizon, according to the Trump Organization, now led by President Donald Trump's children while he is in office. In the ad, an image of the 6.8-inch phone screen is displayed above Trump's slogan, 'Make America Great Again' and a cropped image of the American flag. The phone has a fingerprint sensor and an artificial intelligence face unlock. The T1 Phone is available for pre-order as of June 16 ahead of its September release. It is described as a 'sleek, gold smartphone engineered for performance and proudly designed and built in the United States for customers who expect the best from their mobile carrier.' The phone's marketing may be all-American but it's unclear if the Trump Organization will be able to manufacture these devices in the U.S. at such a low price. 'The country lacks much of the necessary infrastructure to produce smartphones,' as The New York Times notes. It costs $499 and runs on an Android operating system. 'All-American performance. Everyday price,' the website for Trump Mobile says. The '47″ mobile plan, a 5G network, offers unlimited texting, calling and data, as well as device insurance for $47.45 per month. The price holds a meaning: Trump was the 45th president and was reelected to serve as the 47th in 2024. Donald Trump Jr. and Eric Trump, the president's eldest and third-eldest children, announced the initiative at the Trump Tower in Manhattan on Monday. 'We are going to be introducing an entire package of products where people can come and they can get telemedicine on their phones for one flat monthly fee, roadside assistance on their cars, unlimited texting to 100 countries around the world,' said Trump Jr. The announcement came on the same day as the 10-year anniversary of the day Trump came down the golden escalator at the very same Trump Tower and launched his candidacy for president. It also raises ethical concerns about the sitting president's children using the Trump name for monetization. Scott Lincicome, the vice president of Cato Institute, a libertarian think tank, in a post on X, also pointed out this business could benefit from the Trump White House's controversial tariff policies. 'So the guy who can singlehandedly set U.S. tariffs on smartphones is launching his own U.S. smartphone company,' Lincicome said, 'do I have that right?' This venture is in addition to other Trump family sales pitches — including for Bibles, sneakers, watches and cryptocurrency — rolled out since the start of Trump's political career. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
This Clean Energy Penny Stock Has U.S. Military Backing. Should You Buy It Now?
At the end of May, Hyliion (HYLN) caught the market's eye with a breakthrough that turned the tide in its favor. The company secured selection from the Air Force and the Department of Defense's Chief Digital and Artificial Intelligence Office to meet a critical operational need. Hyliion will supply its KARNO power modules which will help the Air Force maintain essential functions during fuel supply disruptions by effortlessly switching between available fuels. Investors reacted swiftly, sending HYLN stock up by 50% on May 28. The 'Golden Era' for Tesla Starts June 22. Should You Buy TSLA Stock First? 3 Highly-Rated Dividend Stocks You've Probably Never Heard Of (But Should) AMD Just Landed a New Microsoft Partnership. Should You Buy AMD Stock Here? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! Having earned status to directly support the Air Force, Hyliion now stands on firmer ground and can help the military's shift toward a more flexible and resilient energy framework. With a significant catalyst behind it and a nearly 50% upside potential, how should you play HYLN stock here? Hyliion (HYLN), is currently valued at $251 million. The company develops generators for stationary and mobile use. Its flagship KARNO generator operates on conventional fuels, landfill and wellhead gas, plus renewable hydrogen and ammonia, delivering versatile, efficient distributed power solutions across a wide range of energy sources. Despite the broader market winds pushing against it, with a year-to-date decline of 47.5%, HYLN has now turned the tables. Over the past month, the stock has climbed by nearly 9%, in attempt to turnaround its story. On May 13, Hyliion released its first-quarter earnings report for 2025, revealing results that fell short of Wall Street's projections. The company reported revenue of $489,000, primarily derived from research and development services under its contract with the Office of Naval Research. The figure lagged the anticipated $1.1 million. The cost of revenue stood at $477,000, leading to a near-breakeven gross margin for the quarter. Operating expenses climbed 3.9% to $19.7 million, driven by an increase in R&D spending, which surged to $12.2 million from $8 million in Q1 2024. The jump reflected intensified activity in additive manufacturing, procurement of long-lead components, and escalating costs tied to ongoing development of KARNO Power Modules. The bottom line showed net loss widening 10.7% to $17.3 million. Loss per share grew 11.1% year over year coming in at $0.10, missing the expected $0.08 per-share loss. Consequently, the company now anticipates full-year 2025 cash outlays around $65 million, an increase from its previous $60 million guidance. Hyliion has maintained its full-year revenue guidance of $10 million to $15 million, propelled by KARNO module sales and ongoing R&D services, while projecting a year-end cash and investment balance near $155 million. Analysts, meanwhile, foresee the Q2 loss per share widening by 50% to $0.09 and full-year 2025 losses increasing by 17.9% to $0.33. The outlook for 2026, however, shows a silver lining, with loss per share expected to narrow by 3% to $0.32. Despite unveiling fresh developments and forging new collaborations, Hyliion finds itself grappling with sluggish revenue growth and mounting operational expenses. A single announcement of a military partnership, while promising, falls short of igniting strong investor confidence in the stock. Currently, HYLN carries a 'Hold' consensus with only one analyst in coverage. That analyst has a price target of $2 on shares, representing upside potential of nearly 50%. On the date of publication, Aanchal Sugandh did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
2 hours ago
- Yahoo
Vertex (VRTX) Stock PT Lowered to $420 on slower Alyftrek Uptake
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 10 biotech stocks screaming a buy. On June 17, RBC Capital reiterated a Sector Perform rating on the stock but cut the price target to $420 from $423. The adjustment is in response to the company confirming gradual patient conversion from Trikafta to the company's next-generation cystic fibrosis treatment, Alyftrek. A research team in lab coats testing a new ImmunoPhage platform in a modern biotechnology lab. RBC Capital remains concerned about the gradual conversion compared to consensus expectations. Consequently, it has warned it could affect the company's operating margins by up to 2%. Nevertheless, the research firm insists that the company's cystic fibrosis franchise remains well-insulated from sector headwinds. However, RBC Capital has reiterated that Vertex could require stronger execution to adopt Alyftrek to justify the current valuation in the market. Consequently, its reduced price target reflects lower year Alyftrek conversion rates. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a global biotechnology company that develops and commercializes therapies for serious diseases. They are known for their work in cystic fibrosis (CF) and are expanding into other areas like cell and genetic therapies. While we acknowledge the potential of VRTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
